The prognosis and treatment consideration for non-small cell lung carcinoma patients with tumor size of >2.0–3.0 cm and visceral pleural invasion: a SEER-based study Authors: Xirui Lin, Haijie Xu, Jianrong Chen, Jiaying Wu, Jiong Lin, Hansheng Wu Published: 2024 ABSTRACT BackgroundLung cancer is the most prevailing oncological disease worldwide. Visceral pleural invasion (VPI) has been proven to be a poor prognosis factor for early-stage non-small cell lung carcinoma (NSCLC) patients. However, there remains some debate regarding whether NSCLC patients with tumor size (TS) ranging from >2.0 to 3.0 cm and VPI should be considered for postoperative treatment. This study compared the prognosis of T2a and T2b NSCLC patients, specifically focusing on those with VPI and TS ranging from >2.0–3.0 cm to emphasize the severity of the disease. Additionally, the impact of adjuvant therapies on the outcome of these patients was discussed.MethodsThis retrospective research utilized data from the Surveillance, Epidemiology, and End Results (SEER) database, which provided a comprehensive dataset of 10,452 patients diagnosed with pN0M0 NSCLC with TS intervals of >2.0–5.0 cm between 2010 and 2019. The SEER database, renowned for its expansive and population-based cancer data, provides a robust platform for researchers to access a large cohort of patients diagnosed with NSCLC. Survival probabilities were calculated by the Kaplan-Meier method and compared between groups with Log-rank test. Univariate and multivariate logistic analyses were used to identify independent risk factors of VPI.ResultsPatients with NSCLC and TS between >2.0 and 3.0 cm, along with VPI, had a worse 5-year overall survival rate compared to those at T2a stage (49.1% vs. 56.8%, P=0.03) and T2b stage (45.4% vs. 64.2%, P<0.0001). However, no statistical significance was observed when comparing patients with TS range between >2.0 and 3.0 cm and presenting with VPI to those staged T2b and received adjuvant chemotherapy (48.4% vs. 48.5%, P=0.54). Patients with clinical stage of T1c and VPI positive had significantly better prognosis after receiving chemotherapy (34.5% vs. 55.2%, P<0.001). Logistic analysis indicated that age older than 65 years old, poor differentiated and undifferentiated, as well as sub-lobectomy resection were independent risk factors for VPI in NSCLC.ConclusionsPostoperative chemotherapy can improve the prognosis of patients with TS ranging from >2.0 to 3.0 cm with VPI. According to the analysis of OS based on the postoperative chemotherapy, patients with NSCLC featuring TS extend from >2.0 to 3.0 cm and VPI may be classified within stage IIA. Consequently, the consideration of postoperative chemotherapy for this patient cohort may be warranted. Highlight box Key findings • In the context of non-small cell lung carcinoma (NSCLC), patients with tumor size between >2.0 to 3.0 cm and visceral pleural invasion (VPI) have comparable prognosis with stage IB patients and may benefit from postoperative adjuvant therapy. What is known and what is new? • Regarding patients with NSCLC <3.0 cm and VPI, current guidelines recommend to upgrade their T stage to T2. However, there is still controversy about whether these patients should be categorized as T2a or T2b and subsequently treated as stage IB or IIA. • The present study focused on patients with NSCLC between >2.0 to 3.0 cm and VPI. We compared their prognosis with T2a and T2b patients to highlight the severity of the disease. Additionally, we also discussed the impact of adjuvant therapies on the outcome of these patients. What is the implication, and what should change now? • Patients with NSCLC between >2.0–3.0 cm and VPI can be treated as stage IIA and the application of postoperative chemotherapy may be considered. Introduction Background Lung cancer is the most common cancer type and the leading cause of cancer-related death worldwide (1). Non-small cell lung carcinoma (NSCLC) accounts for 80% of lung cancer (1). The Global Cancer Statistics 2020 data indicates that the 5-year overall survival (OS) rate of lung cancer is about 10–20% in the majority of countries. Visceral pleural invasion (VPI) is defined as cancer cells invading elastic layers of visceral pleural and has been proven to be a poor prognostic factor for early-stage NSCLC patients (2,3). According to current guideline, VPI can be classified into four levels: tumor invades subpleural lung parenchyma or superficially into the connective tissue (PL0); tumor invades beyond the elastic layer of visceral pleura (PL1); tumor invades the visceral pleural surface (PL2); tumor invades into parietal pleura or chest wall (PL3) (4). The Surveillance, Epidemiology, and End Results (SEER) database is a national cancer epidemiology database with extensive and representative data collection of cancer patient information from across the United States. Several previous studies have also examined the prognostic impact of VPI on lung cancer utilizing the SEER database. Qi et al. [2021] conducted an analysis on the prognostic implications of VPI and recommended upgrading stage of early-stage NSCLC cases exhibiting VPI and tumor size (TS) between 3.1 and 4.0 cm, utilizing data from the SEER database (5). Fang et al. [2022] redefined the T stage of NSCLC in the SEER database based on the degree of VPI and lymph node metastasis (6). Rationale and knowledge gap In accordance with the 8th edition of the American Joint Committee on Cancer (AJCC) staging manual, pN0M0 NSCLC patients with TS below 5.0 cm can be divided into stage T1 (TS ≤3.0 cm), T2a (3.0< TS ≤4.0 cm) and T2b (4.0 2.0 to 3.0 cm and VPI (+) (5,6,8,9). Objective The present study focused on pN0M0 NSCLC patients with TS <3 cm and VPI (+). We compared their prognosis with T2a and T2b patients to highlight the severity of the disease. Additionally, we also discussed the impact of adjuvant therapies on the outcome of these patients. We present this article in accordance with the STROBE reporting checklist (available at https://tcr.amegroups.com/article/view/10.21037/tcr-24-33/rc). Methods Study population This study included 10,452 patients who were diagnosed with NSCLC from 2010 to 2019 in the SEER database (www.seer.cancer.gov/seerstat). Inclusion criteria were as follows: (I) patients who had been diagnosed with NSCLC and the location code in SEER was C34.0–C34.9; (II) patients who had only one primary cancer; (III) patients with TS between >2.0–5.0 cm. Exclusion criteria were as follows: (I) age less than 20 years old; (II) with metastatic diseases; (III) unknown tumor location, grade, histology type, and size; (IV) unknown VPI status or PL3; (V) patients without surgery; (VI) patients with unknown survival information or survive less than 1 month. The flowchart of data processing is shown in Figure 1. We exported the following characteristics of each enrolled patient from the SEER database: patient ID, age, gender, race, histological type, pathological grade, location, TS, VPI status, tumor-node-metastasis (TNM) stage, surgical approach, adjunctive therapy, survival information. The T stage of these patients was reclassified in accordance with the 8th edition of TNM classification. Flowchart of patient selection. NSCLC, non-small cell lung carcinoma; SEER, Surveillance, Epidemiology, and End Results; VPI, visceral pleural invasion; PL0, tumor invades subpleural lung parenchyma or superficially into the connective tissue; PL1, tumor invades beyond the elastic layer of visceral pleura; PL2, tumor invades the visceral pleural surface; PL3, tumor invades into parietal pleura or chest wall. The VPI status was exported from cs site-specific factor 2 (codes 00, 10, 20, 30) and visceral and parietal pleural invasion recode (PL0, PL1 or PL2, PL3) in the SEER database. We reclassified the grade into low grade (well-differentiated, moderate differentiate) and high grade (poor differentiate, undifferentiated). The surgical approach was reclassified into sub-lobular resection (codes 21–22) and lobular resection (codes 30–80). According to the ICD-O-3 coding system, the histology code of NSCLC was composed of adenocarcinoma (8140, 8144, 8200, 8250-8255, 8260, 8310, 8323, 8480, 8481, 8490, 8550), squamous cell carcinoma (8052, 8070-8075, 8083-8084) and other NSCLC (8012-8014, 8022, 8030-8032, 8050, 8082, 8123, 8230, 9240, 8249, 8430,8560, 8980) (10,11). The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Grouping of patients Patients were divided into different groups based on their TS, VPI status (+, with; −, without), and postoperative chemotherapy status (+, with; −, without). The details of the grouping are listed in Table 1. Group A: TS extends from >2.0 to 3.0 cm with VPI (+) and postoperative chemotherapy (+); Group B: TS extends from >2.0 to 3.0 cm with VPI (+) and postoperative chemotherapy (−); Group C: TS extends from >3.0 to 4.0 cm with VPI (+/−) and postoperative chemotherapy (−); Group D: TS extends from >4.0 to 5.0 cm with VPI (+/−) and postoperative chemotherapy (+); Group E: TS extends from >4.0 to 5.0 cm with VPI (+/−) and postoperative chemotherapy (−). Table 1Grouping of the study populationGroupTumor size (cm)VPIPostoperative chemotherapyNumberA>2.0 to 3.0PositiveYes221B>2.0 to 3.0PositiveNo1,174C>3.0 to 4.0Positive/negativeNo2,566D>4.0 to 5.0Positive/negativeYes412E>4.0 to 5.0Positive/negativeNo1,028VPI, visceral pleural invasion. Grouping of the study population VPI, visceral pleural invasion. Statistical analysis Demographic and clinical characteristics were described using numbers (percentage). Categorical variables were compared using Pearson’s χ2 test or Fisher’s exact test. Propensity score matching (PSM) was performed with the nearest-neighbor method (matching ratio =1:1, caliper =0.02) to balance the baseline characteristics between different groups. OS was defined as the duration from the diagnosis of cancer to the date of death or last follow-up date. The survival curves were calculated by Kaplan-Meier and compared with the Log-rank test between groups. Univariate and multivariate logistic regression were used to identify independent risk factors for VPI. All statistical tests conducted were two-tailed, with a significance threshold set at P<0.05. The statistical analyses were executed using R software, version 4.2.3 (http://www.r-project.org/). Results Baseline characteristics of the study cohort According to the inclusion and exclusion criteria, a total of 10,452 NSCLC patients with TS interval of >2.0–5.0 cm were included in the study (Figure 1). The baseline characteristics of patients are listed in Table 2. The number of patients with or without VPI in the general study population was 2,708 (25.9%) and 7,744 (74.1%), respectively. The proportion of patients with age over 65 years old, tumor in the upper lobe, lower pathological grade, adenocarcinoma, sub-lobar resection, and adjunctive therapy, was significantly lower in the VPI negative group compared to the VPI positive group (P<0.05). Table 2Baseline characteristics of patients with TS interval >2.0–5.0 cmVariablesVPI negative (n=7,744)VPI positive (n=2,708)P valueAge, years<0.001 <652,646 [34]806 [30] ≥655,098 [66]1,902 [70]Gender0.44 Female4,071 [53]1,447 [53] Male3,673 [47]1,261 [47]Race0.002 White6,402 [83]2,174 [80] Black639 [8]226 [8] Others703 [9]308 [12]Location<0.001 Upper lobe4,475 [58]1,693 [63] Lower lobe2,652 [34]778 [29] Others617 [8]237 [8]Laterality0.28 Left side3,129 [40]1,062 [39] Right side4,615 [60]1,646 [61]Grade<0.001 Low grade5,260 [68]1,586 [59] High grade2,484 [32]1,122 [41]Histologic type<0.001 Adenocarcinoma4,538 [59]1,789 [66] Squamous cell carcinoma2,261 [29]697 [26] Others945 [12]222 [8]Tumor size, cm<0.001 >2.0 to 3.04,579 [59]1,385 [51] >3.0 to 4.02,152 [28]842 [31] >4.0 to 5.01,013 [13]481 [18]Surgical type,<0.001 Sub-lobular resection980 [13]418 [15] Lobular resection6,764 [87]2,290 [85]Adjuvant therapy<0.001 Yes877 [11]644 [24] No6,867 [89]2,064 [76]Values are presented as n [%]. Low grade, well and moderate differentiate; high grade, poor differentiate and undifferentiated. TS, tumor size; VPI, visceral pleural invasion. Baseline characteristics of patients with TS interval >2.0–5.0 cm Values are presented as n [%]. Low grade, well and moderate differentiate; high grade, poor differentiate and undifferentiated. TS, tumor size; VPI, visceral pleural invasion. Patients with TS between >2.0–3.0 cm and VPI (+) have a worse prognosis than T2 tumor The overall analysis flowchart is shown in the Figure 2. Survival analysis before PSM is shown in Figure S1. Since some variables were significantly different between groups, the effect of confounders was eliminated by PSM. The variables that listed in the PSM included: age, gender, race, location, laterality, grade, histology, surgical type, and adjunctive therapy. To assess the difference in outcomes among individuals without postoperative treatment in their natural state, we examined the prognoses of patients who did not receive postoperative chemotherapy and analyzed the difference in their prognoses. Risk factors of VPI in the study cohort. TS, tumor size; VPI, visceral pleural invasion. Table 3 shows the characteristics of patients with TS intervals of >2.0–3.0 cm (Group B) and >3.0–4.0 cm (Group C) without postoperative chemotherapy before and after PSM. There were 1,174 patients in Group B and 2,566 patients in Group C. After PSM, the number of patients in each group was matched to 642. The result of OS is shown in Figure 3A. The 5-year OS of patients in Group B and Group C was 49.1% and 56.8%, respectively. The difference in prognosis between these groups were significant (P=0.03) and the prognosis of Group B was worse than that of Group C. Table 3Characteristics of Group B vs. Group C before and after PSMVariablesBefore PSMAfter PSMGroup B (n=1,174)Group C (n=2,566)P valueGroup B (n=642)Group C (n=642)P valueAge, years0.030.41 <65315 [27]776 [30]163 [25]176 [27] ≥65859 [73]1,790 [70]479 [75]466 [73]Gender0.0050.74 Female656 [56]1,307 [51]342 [53]404 [63] Male518 [44]1,259 [49]300 [47]238 [37]Race0.030.63 White931 [79]2,125 [83]519 [81]506 [79] Black108 [9]186 [7]46 [7]48 [7] Others135 [12]255 [10]77 [12]88 [14]Location0.0020.09 Upper lobe741 [63]1,485 [58]396 [62]374 [58] Lower lobe332 [28]878 [34]195 [30]194 [30] Others101 [9]203 [8]51 [8]74 [12]Laterality0.180.14 Left side447 [38]1,037 [40]262 [41]236 [37] Right side727 [62]1,529 [60]380 [59]406 [63]Grade0.800.87 Low grade764 [65]1,659 [65]385 [60]382 [60] High grade410 [35]907 [35]257 [40]260 [40]Histologic type<0.0010.65 Adenocarcinoma829 [71]1,436 [56]408 [64]402 [63] Squamous cell carcinoma258 [22]853 [33]187 [29]184 [29] Other NSCLC87 [7]277 [11]47 [7]56 [8]Adjunctive therapy0.740.68 No1,130 [96]2,464 [96]615 [96]612 [95] Yes44 [4]102 [4]27 [4]30 [5]Surgical type<0.0010.34 Sub-lobular resection237 [20]287 [11]88 [14]100 [16] Lobular resection937 [80]2,279 [89]554 [86]542 [84]Values are presented as n [%]. Group B, NSCLC patients with TS interval of >2.0–3.0 cm and VPI are positive without postoperative chemotherapy; Group C, NSCLC patients with TS interval of >3.0–4.0 cm and without postoperative chemotherapy. Low grade, well and moderate differentiate; high grade, poor differentiate and undifferentiated. PSM, propensity score matching; NSCLC, non-small cell lung carcinoma; TS, tumor size; VPI, visceral pleural invasion. Characteristics of Group B vs. Group C before and after PSM Values are presented as n [%]. Group B, NSCLC patients with TS interval of >2.0–3.0 cm and VPI are positive without postoperative chemotherapy; Group C, NSCLC patients with TS interval of >3.0–4.0 cm and without postoperative chemotherapy. Low grade, well and moderate differentiate; high grade, poor differentiate and undifferentiated. PSM, propensity score matching; NSCLC, non-small cell lung carcinoma; TS, tumor size; VPI, visceral pleural invasion. Kaplan-Meier survival curves between groups. (A) OS of patients with TS interval of >2.0–3.0 and >3.0–4.0 cm who did not received postoperative chemotherapy; (B) OS of patients with TS interval of >2.0–3.0 and >4.0–5.0 cm who did not received postoperative chemotherapy; (C) OS of patients with TS interval of >2.0–3.0 and >4.0–5.0 cm who received postoperative chemotherapy; (D) OS of patients with TS interval of >2.0–3.0 cm with and without postoperative chemotherapy. VPI, visceral pleural invasion; TS, tumor size; OS, overall survive. Similarly, Table 4 shows the characteristics of the TS of >2.0–3.0 cm (Group B) and >4.0–5.0 cm (Group E) without postoperative chemotherapy. There were 334 patients in Group B and Group E after PSM respectively. Figure 3B shows that the 5-year OS for Group B and Group E were 45.4% and 64.2%, respectively. The difference between Group B and Group E was significant (P<0.001) and the prognosis of patients in Group B was poorer than that of Group E. Table 4Characteristics of Group B and Group E before and after PSMVariableBefore PSMAfter PSMGroup B (n=1,174)Group E (n=1,082)P valueGroup B (n=334)Group E (n=334)P valueAge, years0.890.44 <65315 [27]293 [27]70 [21]62 [19] ≥65859 [73]789 [73]264 [79]272 [81]Gender<0.0010.88 Female656 [56]493 [46]152 [46]150 [45] Male518 [44]589 [54]182 [54]184 [55]Race0.120.56 White931 [79]887 [82]276 [83]232 [70] Black108 [9]99 [9]29 [9]72 [21] Others135 [11]96 [9]29 [9]30 [9]Location0.0010.49 Upper lobe741 [63]608 [56]195 [58]210 [63] Lower lobe332 [28]387 [36]115 [34]103 [31] Others101 [9]87 [8]24 [7]21 [6]Laterality0.280.64 Left side447 [38]436 [40]136 [41]130 [39] Right side727 [62]646 [60]198 [59]204 [61]Grade0.88 Low grade764 [65]616 [57]178 [53]176 [53] High grade410 [35]466 [43]156 [47]158 [47]Histologic type0.0010.86 Adenocarcinoma829 [71]542 [50]187 [56]194 [58] Squamous cell carcinoma258 [22]416 [38]117 [35]112 [34] Other NSCLC87 [7]124 [11]30 [9]28 [8]Surgical type<0.0010.89 Sub-lobular resection237 [20]80 [7]29 [9]28 [8] Lobular resection937 [80]1,002 [93]305 [91]306 [92]Values are presented as n [%]. Group B, NSCLC patients with TS interval of >2.0–3.0 cm and VPI positive without postoperative chemotherapy; Group E, NSCLC patients with TS interval of >4.0–5.0 cm and without postoperative chemotherapy. Low grade, well and moderate differentiate; high grade, poor differentiate and undifferentiated. PSM, propensity score matching; TS, tumor size; VPI, visceral pleural invasion; NSCLC, non-small cell lung carcinoma. Characteristics of Group B and Group E before and after PSM Values are presented as n [%]. Group B, NSCLC patients with TS interval of >2.0–3.0 cm and VPI positive without postoperative chemotherapy; Group E, NSCLC patients with TS interval of >4.0–5.0 cm and without postoperative chemotherapy. Low grade, well and moderate differentiate; high grade, poor differentiate and undifferentiated. PSM, propensity score matching; TS, tumor size; VPI, visceral pleural invasion; NSCLC, non-small cell lung carcinoma. Postoperative chemotherapy can improve prognosis of patients with T1c tumor and VPI Given the unfavorable prognosis for patients with T1c tumor and VPI, we conducted a comparative analysis of the prognosis in patients with TS of >2.0–3.0 cm who underwent postoperative therapy (Group A) and those who did not receive such treatment (Group B). The objective of this analysis was to explore the potential benefits of adjuvant therapy in improving the prognosis of these patients. Table 5 shows the characteristics of Group A and Group B. After PSM, between-group differences for all variables were eliminated. Survival analysis demonstrated that patients in Group A had a significantly better 5-year OS than patients in Group B (55.2% vs. 34.5%, P<0.001, Figure 3C). Table 5Characteristics of Group A vs. Group B before and after PSMVariableBefore PSMAfter PSMGroup A (n=221)Group B (n=1,174)P valueGroup A (n=204)Group B (n=204)P valueAge, years0.0010.92 <6594 [45]315 [27]88 [43]89 [44] ≥65117 [55]859 [73]116 [57]115 [56]Gender,0.520.69 Female123 [58]656 [56]118 [58]122 [60] Male88 [42]518 [44]86 [42]82 [40]Race0.980.72 White166 [79]931 [79]161 [79]167 [82] Black20 [9]108 [9]19 [9]15 [7] Others25 [12]135 [12]24 [12]22 [11]Location0.0090.99 Upper lobe139 [66]741 [63]138 [68]139 [68] Lower lobe43 [20]332 [28]43 [21]43 [21] Others29 [14]101 [9]23 [11]22 [11]Laterality0.390.76 Left side87 [41]447 [38]84 [41]87 [43] Right side124 [59]727 [62]120 [59]117 [57]Grade0.0010.77 Low grade106 [50]764 [65]102 [50]105 [51] High grade105 [50]410 [35]102 [50]99 [49]Histologic type0.350.92 Adenocarcinoma157 [74]829 [71]152 [75]153 [75] Squamous cell carcinoma37 [18]258 [22]37 [18]38 [19] Other NSCLC17 [8]87 [7]15 [7]13 [6]Surgical type0.800.90 Sub-lobular resection41 [19]237 [20]41 [20]40 [20] Lobular resection170 [81]937 [80]163 [80]164 [80]Values are presented as n [%]. Group A, NSCLC patients with TS interval of >2.0–3.0 cm and VPI positive with postoperative chemotherapy; Group B, NSCLC patients with TS interval of >2.0–3.0 cm and VPI positive without postoperative chemotherapy. Low grade, well and moderate differentiate; high grade, poor differentiate and undifferentiated. PSM, propensity score matching; NSCLC, non-small cell lung carcinoma; TS, tumor size; VPI, visceral pleural invasion. Characteristics of Group A vs. Group B before and after PSM Values are presented as n [%]. Group A, NSCLC patients with TS interval of >2.0–3.0 cm and VPI positive with postoperative chemotherapy; Group B, NSCLC patients with TS interval of >2.0–3.0 cm and VPI positive without postoperative chemotherapy. Low grade, well and moderate differentiate; high grade, poor differentiate and undifferentiated. PSM, propensity score matching; NSCLC, non-small cell lung carcinoma; TS, tumor size; VPI, visceral pleural invasion. T1c tumor with VPI exhibits a comparable prognosis to stage IIA tumor after chemotherapy To assess whether patients with T1c tumor and VPI have a similar prognosis to stage IIA patients, we conducted a comparison between Group A and patients with TS between >4.0 and 5.0 cm who received chemotherapy (Group D). Table 6 shows the characteristics of patients in Group A and Group D. After PSM, there were 104 patients in both Group A and Group D, respectively. The 5-year OS of patients in Group A and Group D were 48.4% and 48.5%, respectively (Figure 3D). There was no between-group difference in survival (P=0.54). Table 6Characteristics of Group A vs. Group D before and after PSMVariableBefore PSMAfter PSMGroup A (n=221)Group D (n=412)P valueGroup A (n=104)Group D (n=104)P valueAge, years0.440.58 <6594 [45]197 [48]49 [47]45 [43] ≥65117 [55]215 [52]55 [53]59 [57]Gender0.0010.89 Female123 [58]178 [43]56 [54]57 [55] Male88 [42]234 [57]48 [46]47 [45]Race0.330.16 White166 [79]341 [83]89 [86]83 [80] Black20 [9]37 [9]9 [9]7 [7] Others25 [12]34 [8]6 [5]14 [13]Location0.0010.27 Upper lobe139 [66]228 [55]68 [65]57 [55] Lower lobe43 [20]155 [38]27 [26]33 [32] Others29 [14]29 [7]9 [9]14 [13]Laterality0.27>0.99 Left side87 [41]151 [37]33 [32]33 [32] Right side124 [59]261 [63]71 [68]71 [68]Grade0.730.49 Low grade106 [50]201 [49]48 [46]43 [41] High grade105 [50]211 [51]56 [54]61 [59]Histologic type0.0010.83 Adenocarcinoma157 [74]224 [54]68 [65]69 [66] Squamous cell carcinoma37 [18]143 [35]27 [26]24 [23] Other NSCLC17 [8]45 [11]9 [9]11 [11]Surgical type0.0010.82 Sub-lobular resection41 [19]24 [6]11 [11]10 [10] Lobular resection170 [81]388 [94]93 [89]94 [90]Values are presented as n [%]. Group A, NSCLC patients with TS interval of >2.0–3.0 cm and VPI positive with postoperative chemotherapy; Group D, NSCLC patients with TS interval of >4.0–5.0 cm and with postoperative chemotherapy. Low grade, well and moderate differentiate; high grade, poor differentiate and undifferentiated. PSM, propensity score matching; NSCLC, non-small cell lung carcinoma; TS, tumor size; VPI, visceral pleural invasion. Characteristics of Group A vs. Group D before and after PSM Values are presented as n [%]. Group A, NSCLC patients with TS interval of >2.0–3.0 cm and VPI positive with postoperative chemotherapy; Group D, NSCLC patients with TS interval of >4.0–5.0 cm and with postoperative chemotherapy. Low grade, well and moderate differentiate; high grade, poor differentiate and undifferentiated. PSM, propensity score matching; NSCLC, non-small cell lung carcinoma; TS, tumor size; VPI, visceral pleural invasion. Risk factors of VPI In this study, logistic regression analysis was employed to identify the risk factors associated with VPI in patients with a TS interval ranging from >2.0 to 5.0 cm. Figure 4 shows the result of risk factors of NSCLC patients with VPI in this study cohort. In each subgroup, we can conclude that age greater than 65 years old (OR: 1.33, 95% CI: 1.21–1.47, P<0.001), lesions not located in upper and lower lobe (OR: 1.06, 95% CI: 0.90–1.26, P<0.001), poor differentiated and undifferentiated (OR: 0.59, 95% CI: 0.50–0.69, P<0.001), sublobectomy resection (OR: 1.22, 95% CI: 1.07–1.39, P=0.002) were prognostic risk factors of VPI. Flowchart of analysis of the study cohort. OR, odds ratio; CI, confidence interval; SCC, squamous cell carcinoma; NSCLC, non-small cell lung carcinoma. Discussion VPI has been listed as a characteristic indicator in the TNM classification of the International Union Against Cancer staging system (12). According to the 8th edition of TNM, NSCLC patients with TS less than 3.0 cm and VPI (+) should upgrade from T1 to T2. However, whether T1cN0M0 NSCLC patients with VPI (+) should be classified alongside with stage IB or stage IIA is yet to be decided, which leads to a discussion about whether early-stage NSCLC patients with VPI should receive postoperative anti-neoplastic agents combined treatment. Our study focused on analyzing primary NSCLC patients diagnosed between 2010–2019, using data obtained from the SEER database. Specifically, we aimed to compare the prognosis of different patient groups based on their receipt of postoperative chemotherapy and the presence of VPI. The results indicated that NSCLC patients with TS extends from >2.0 to 3.0 cm and VPI (+) had a better prognosis if they received postoperative chemotherapy as stage IIA. However, there are some conflicts about the postoperative treatment regimen of early-stage NSCLC patients with VPI (+). According to the American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline, NSCLC patients with stage IIA should receive cisplatin-based adjuvant chemotherapy as routine after complete surgical resection. However, for patients with stage IB, routine cisplatin-based adjuvant chemotherapy is not recommended (13). Whether patients with TS interval of >2.0–3.0 cm and VPI (+) should be grouped with stage IB or stage IIA is still not determined which directly impacts the selection of postoperative treatment for these patients. In previous studies, according to the study by Kim et al. [2024], their findings suggest that adjuvant chemotherapy is suitable for individuals with stage IB NSCLC with VPI, including those with smaller tumors ranging from 1.0 to 3.0 cm (14). Yoshida et al. and Lakha et al. both indicate that the T stage of all NSCLC patients with TS less than 7.0 cm with VPI should be upgraded in further TNM classification which also shares the same conclusion as our research (9,15). Xie et al. [2020] reported that postoperative chemotherapy had no effects on the VPI patients in stage IB (16). Liang et al. [2021] showed that NSCLC patients with TS of 3.0 cm and PL2 should be graded into stage IB (17). Nitadori et al. [2013] indicated that the VPI-positive patients with TS ranging from >2.0 to 3.0 cm should be graded into new stage IB (18). During our analysis of the study cohort, there was a significant difference in the prognosis between TS interval of >2.0–3.0 and >3.0–4.0 cm who did not receive postoperative chemotherapy. Additionally, a significant difference in prognosis was also observed between TS interval of >2.0–3.0 and >4.0–5.0 cm who did not undergo postoperative chemotherapy. Based on our findings, it can be concluded that VPI (+) patients with TS interval of >2.0–3.0 cm exhibit a worse prognosis compared to patients with TS interval of >3.0–5.0 cm and VPI (+/−). These results suggest that patients with TS interval of >2.0–3.0 cm and VPI (+) should not be classified as a stage below IB. Secondly, there was a similar prognosis of patients with TS interval of >2.0–3.0 and >4.0–5.0 cm who received postoperative chemotherapy which means VPI patients with TS interval of >2.0–3.0 cm should be graded as T2bN0M0 patients to receive postoperative chemotherapy. On the other hand, we conducted a comparison of the OS curve between VPI (+) patients with a TS interval of >2.0–3.0 cm who received postoperative chemotherapy and those who did not. The analysis revealed that patients who underwent postoperative chemotherapy exhibited better prognosis. It follows that postoperative chemotherapy can help to improve the prognosis of patients with TS ranging from >2.0 to 3.0 cm with VPI. With the development of target therapy and immunotherapy, postoperative adjuvant therapy is not limited to chemotherapy and/or radiotherapy (19). As the ADAURA trial has shown that the use of osimertinib after surgical resection can improve outcomes in patients with stage IB–IIIA NSCLC with EGFR mutation (20). Although stage IB patients with TS ranging from >2.0 to 3.0 cm and VPI positive were not included in this study, previous studies have shown that there may be a close relationship between VPI and some gene mutation. Shi et al. concluded that there is a significant relationship between EGFR mutations and VPI (21). Another retrospective study involving 80 NSCLC patients showed that patients with advanced NSCLC with KRAS mutation who received chemotherapy had a better prognosis than those who did not receive first-line chemotherapy which means KRAS mutation may also be associated with VPI (22,23). In terms of adjuvant immunotherapy after lung cancer surgery, in a study of 1,280 patients treated with atezolizumab after surgery for stage II–IIIA NSCLC, Felip found that the use of atezolizumab after surgery improved disease-free survival (DFS) of patients, particularly in those with 1% or more programmed death-ligand 1 (PD-L1) expression in tumor cells (TCs) (24). In the study by O’Brien M, pembrolizumab significantly improved DFS in patients with completely resected stage IB–IIIA postoperative NSCLC without PD-L1 selection (25). Therefore, it was proposed in the guidelines of the Chinese Society of Clinical Oncology (CSCO) guideline 2023 that after radical surgery, the adjuvant treatment of atezolizumab (limited to PD-L1 TC ≥1%) was upgraded from the grade II recommendation to the grade I recommendation, and pembrolizumab adjuvant treatment was added as the grade II recommendation. It can be seen that adjuvant treatment for NSCLC after surgery has become increasingly abundant. For VPI patients with TS interval of >2.0–3.0 cm after surgery, if further detection of gene mutation or PD-L1 TC ratio can be more beneficial than chemotherapy, it will be an area worth further exploration. Before the lack of clear data on postoperative adjuvant therapy for this group of patients in existing guidelines, we are the first study to explore the relationship between postoperative chemotherapy and prognosis in patients with >2.0–3.0 cm NSCLC complicated with VPI. Moreover, our sample size is large, including patients with primary NSCLC diagnosed from 2010 to 2019 in the SEER database. The primary distinction between the treatment approaches for stage IB and stage IIA is the administration of postoperative chemotherapy. Based on our findings, we recommend that postoperative chemotherapy should be included in the recommended regimen for VPI (+) patients with TS interval of >2.0–3.0 cm. In this study, there are still some limitations. Since the data from this research were extracted from the SEER database, which lacked information on the patient’s smoking history, we cannot discuss this risk factor of VPI. In addition, as some data in SEER did not classify the VPI state into PL1 or PL2, the specific role in the VPI subgroup cannot be discussed. Beyond that, the patients who received postoperative chemotherapy from the SEER database were selected by clinicians, these patients may be those the clinicians perceive as having a worse prognosis. An additional confounding factor may have been introduced here. Conclusions Postoperative chemotherapy can improve the prognosis of patients with TS ranging from >2.0 to 3.0 cm with VPI. According to the analysis of OS based on the postoperative chemotherapy, patients with NSCLC featuring TS extend from >2.0 to 3.0 cm and VPI may be classified within stage IIA. Consequently, the consideration of postoperative chemotherapy for this patient cohort may be warranted. Supplementary The article’s supplementary files as Available at https://tcr.amegroups.com/article/view/10.21037/tcr-24-33/prf